Musset M - Search Results

1

[Evaluation of the effect of pathology slide review on clinical practice in an oncology center].

Emile JF, Di Palma M, Musset M, Sebagh M, Auriault ML, Misset JL, Reynès M. Emile JF, et al. Among authors: musset m. Ann Pathol. 2000 Sep;20(4):304-7. Ann Pathol. 2000. PMID: 11015647 French.

2

Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.

Germann N, Brienza S, Rotarski M, Emile JF, Di Palma M, Musset M, Reynes M, Soulié P, Cvitkovic E, Misset JL. Germann N, et al. Among authors: musset m. Ann Oncol. 1999 Mar;10(3):351-4. doi: 10.1023/a:1008310708853. Ann Oncol. 1999. PMID: 10355582 Free article. Clinical Trial.

3

Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

Brain E, Garrino C, Misset JL, Carbonero IG, Itzhaki M, Cvitkovic E, Goldschmidt E, Burki F, Regensberg C, Pappo E, Hagipantelli R, Musset M. Brain E, et al. Among authors: musset m. Br J Cancer. 1997;75(9):1360-7. doi: 10.1038/bjc.1997.230. Br J Cancer. 1997. PMID: 9155059 Free PMC article.

4

Phase I trial of Perrimustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.

Kim-Triana B, Misset JL, Madelmont JC, Godenèche D, Musset M, Mathé G. Kim-Triana B, et al. Among authors: musset m. Anticancer Drugs. 1992 Jun;3(3):225-31. doi: 10.1097/00001813-199206000-00004. Anticancer Drugs. 1992. PMID: 1525402

5

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

Soulié P, Bensmaïne A, Garrino C, Chollet P, Brain E, Fereres M, Jasmin C, Musset M, Misset JL, Cvitkovic E. Soulié P, et al. Among authors: musset m. Eur J Cancer. 1997 Aug;33(9):1400-6. doi: 10.1016/s0959-8049(97)00122-6. Eur J Cancer. 1997. PMID: 9337681 Clinical Trial.

6

Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia.

Blazsek I, Farabos C, Musset M, Goldschmidt E, Comisso M, Benavides M, Wang ZY, Labat ML, Mathé G, Misset JL. Blazsek I, et al. Among authors: musset m. Biomed Pharmacother. 1991;45(4-5):169-77. doi: 10.1016/0753-3322(91)90104-2. Biomed Pharmacother. 1991. PMID: 1932600

7

Combined differentiation therapy in myelodysplastic syndrome with retinoid acid, 1 alpha,25 dihydroxyvitamin D3, and prednisone.

Blazsek I, Musset M, Boulé D, Labat ML, Bringuier MF, Comisso M, Le Maignan C, Ribaud P, Mathé G, Misset JL. Blazsek I, et al. Among authors: musset m. Cancer Detect Prev. 1992;16(4):259-64. Cancer Detect Prev. 1992. PMID: 1458517

8

Relationship between proliferative activity of bone marrow micrometastasis and plasmatic level of a new cancer marker: lipid associated sialic acid (LASA) in human breast cancer.

Ginsbourg M, Musset M, Misset JL, Mathé G. Ginsbourg M, et al. Among authors: musset m. Biomed Pharmacother. 1986;40(10):388-91. Biomed Pharmacother. 1986. PMID: 3580507

9

Simultaneous detection in the bone marrow of mammary cancer metastatic cells and of their labelling index as respective markers of the residual minimum submacroscopic disease and its proliferative condition (preliminary results).

Ginsbourg M, Musset M, Misset JL, Genty O, Mathé G. Ginsbourg M, et al. Among authors: musset m. Biomed Pharmacother. 1986;40(10):386-8. Biomed Pharmacother. 1986. PMID: 3555638

10

Immunomodulating properties of bestatin in cancer patients. A phase II trial.

Mathé G, Umezawa H, Misset JL, Brienza S, Canon C, Musset M, Reizenstein P. Mathé G, et al. Among authors: musset m. Biomed Pharmacother. 1986;40(10):379-82. Biomed Pharmacother. 1986. PMID: 3495299

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters